目的 观察食管鳞癌(ESCC)患者血浆长链非编码RNA(lncRNA) TUC338表达变化,并探讨其诊断ESCC的潜在价值.方法 选择ESCC患者116例(ESCC组)、体检健康者39例(对照组),收集两组空腹静脉血,离心留取血浆;选择ESCC组织及其配对的癌旁正常组织.采用实时荧光定量PCR法检测两组血浆和ESCC组织及癌旁正常组织lncRNA TUC338表达.随机选择46例ESCC患者,采用Spearman秩相关分析法分析血浆与肿瘤组织lncRNA TUC338表达的关系.分析血浆lncRNA TUC338表达与ESCC患者临床病理参数的关系.采用受试者工作特征(ROC)曲线评估血浆lncRNA TUC338表达诊断ESCC的价值.结果 ESCC组血浆lncRNA TUC338相对表达量明显高于对照组(P<0.01).ESCC组织lncRNA TUC338相对表达量明显高于癌旁正常组织(P<0.01).血浆与肿瘤组织lncRNA TUC338表达呈正相关关系(r=0.643,P<0.01).血浆lncRNA TUC338表达与ESCC患者 TNM分期及淋巴结转移有关(P均<0.05).ROC曲线分析显示,血浆lncRNA TUC338表达诊断ESCC的曲线下面积为0.684;其cut off值为1.415,此时其诊断ESCC的敏感性为63.4％,特异性为78.1％.结论 ESCC患者血浆lncRNA TUC338高表达,其表达变化与肿瘤TNM分期、淋巴结转移有关;血浆lncRNA TUC338有可能作为诊断ESCC的潜在生物标志物.

AimsThis study aimed to assess plasma lncRNA microRNA-31 hist gene (MIR31HG) as a novel diagnostic and therapeutic biomarker for esophageal squamous cell carcinoma (ESCC) and to investigate its role in ESCC.Main methodsThe expression of MIR31HG, Furin and MMP1 was examined via quantitative real-time polymerase chain reaction. MIR31HG expression between plasma and ESCC tissues was compared using Pearson correlation analysis; furthermore, the association between Furin/MMP1 levels and MIR31HG levels in ESCC tissues was analyzed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of plasma MIR31HG. A WST-1 assay was performed to assess cell proliferation. The migratability and invasiveness of cells was determined via Transwell assays.Key findingsMIR31HG was significantly upregulated in ESCC tissues and plasma (P < 0.01). A significant positive association was obtained between plasma and tissue MIR31HG expression in ESCC (r = 0.78, P < 0.01). Furthermore, MIR31HG displayed high diagnostic sensitivity and specificity for predicting ESCC occurance. Furthermore, knockdown of MIR31HG suppressed the capacity for proliferation, migration, and invasion of ESCC cells (P < 0.01). In addition, silencing of MIR31HG inhibited the expression of Furin and MMP1 in EC9706 and EC1 and the level of Furin/MMP1 in ESCC tissues displayed a significant positive correlation with MIR31HG (P < 0.01).SignificanceMIR31HG can be used as a novel potential diagnostic biomarker and a potential therapeutic target for ESCC.

Esophageal squamous cell carcinoma (ESCC) is a common human malignancy with poor survival, which was usually diagnosed at an advanced stage. MicroRNAs (miRNAs), a class of single stranded noncoding RNAs with only 17–25 ribonucleotides, were demonstrated to play an important role in lots of cancers. In the recent years, increasing evidence revealed that circulating miRNAs exhibited great potential in the diagnosis of various types of cancers. The present study was designed to evaluate the diagnostic value of plasma miRNA-216a/b for ESCC. Our results showed that the expression level of plasma miRNA-216a/b was significantly lower in ESCC patients compared with that of healthy controls. The receiver operating characteristic (ROC) curve analysis yielded an area under the ROC curve (AUC) value of 0.877 [95% CI (confidence interval): 0.818–0.922] for miRNA-216a and 0.756 (95% CI: 0.685–0.819) for miRNA-216b. Clinical data indicated that plasma miRNA-216a/b were inversely correlated with lymph node metastasis and TNM stage. Additionally, the plasma miRNA-216b expression level was significantly upregulated in postoperative samples compared to preoperative samples. Our study, for the first time, demonstrated that plasma miRNA-216a/b might serve as potential biomarkers for the diagnosis of ESCC and dysregulation of miRNA-216a/b might be involved in the progression of ESCC.

目的 探讨miRNA-205在食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)患者组织中的表达情况.方法 收集56例经病理确诊的ESCC患者的手术切除组织(癌组织及其癌旁组织),采用实时荧光定量聚合酶链式反应(real-time quantitative polymerase chain reaction,qRT-PCR)检测miRNA-205的表达,并分析miRNA-205在不同临床病理资料之间的差异.结果 ESCC患者组织中miRNA-205相对表达量为1.475(0.444～5.478),显著高于癌旁组织(Z=-3.067,P=0.002);miRNA-205在不同TNM分期ESCC患者组织中存在差异,TNM分期越高,miRNA-205表达量越高,差异具有统计学意义(F=36.335,P＜0.001);miRNA-205在淋巴结转移阴性/阳性组织中存在差异,淋巴结转移阳性组miRNA-205表达量显著高于淋巴结转移阴性组(Z=-3.353,P=0.001).结论 miRNA-205在ESCC患者癌组织中表达升高,并可能参与ESCC的发生与发展.

BACKGROUND: Increasing evidence demonstrated that circulating miRNAs could serve as meaningfully non-invasive and reliable biomarkers for the detection of various cancers.OBJECTIVE: To investigate the expression level of plasma miRNA-718 in esophageal squamous cell carcinoma (ESCC) patients and its diagnostic value.METHODS: Quantitative real time polymerase chain reaction (qRT-PCR) method was performed to examine the expression levels of plasma miRNA-718 in 120 consecutive ESCC patients and 51 healthy controls. The difference of plasma miRNA-718 expression level between the paired pre- and postoperative patients was compared. The correlation between plasma miRNA-718 expression levels and clinicopathological characteristics was further analyzed and the receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic power of plasma miRNA-718 for ESCC.RESULTS: Plasma miRNA-718 expression level of ESCC patients was significantly lower than that of healthy controls. Compared with preoperative patients, the plasma miRNA-718 expression level of postoperative patients was significantly upregulated. Plasma miRNA-718 expression level was inversely correlated with the lymph node metastasis and TNM stage. The ROC curve analysis showed that plasma miRNA-718 yielded AUCs of 0.715, 0.689 and 0.620 for the detection of ESCC patients, early patients with Tis-T1 or early patients with TNM 0-I, respectively.CONCLUSION: Plasma miRNA-718 is downregulated in ESCC patients and might serve as a potential diagnostic marker for ESCC.

A total knee arthroplasty (TKA) has always been associated with moderate-to-severe pain. A systematic review of randomized controlled trials (RCTs) and non-RCTs was performed to evaluate the efficacy and safety of pain control of adductor canal block (ACB) and femoral nerve block (FNB) after TKA. Relevant literatures about the ACB and FNB after TKA for reducing pain were searched from Medline (1996-January, 2015), Embase (1980-January, 2015), PubMed (1980-January, 2015), Web of Science (1980-January, 2015), and The Cochrane Central Register of Controlled Trials. High-quality RCTs and non-RCTs were picked to evaluate the visual analogue scale (VAS) and other outcome. This systematic review and meta-analysis were performed according to the PRISMA statement criteria. The software RevMan 5.30 was used for the meta-analysis. Eight literatures fitted into the inclusion criteria. There were no significant differences in VAS score with rest or mobilization at 4, 24, and 48 h between ACB group and FNB group. There were also no significant differences in the strength of quadriceps and adductor, the length of hospital stay, and complications of vomiting and nausea. Present meta-analysis indicated that ACB shows no superiority than FNB group. Both of them can reduce the pain score after TKA. As referred to which method to adopt, it is determined by the preference of the surgeons and anesthesiologists.

MicroRNA (miRNAs) is demonstrated to be present in the blood of humans and has been increasingly suggested as a novel biomarker for various pathological processes in the heart, including myocardial infarction, myocardial remodeling and progression to heart failure. In this study, we aim to evaluate the diagnostic and prognostic value of circulating miR-328 and miR-134 in patients with acute myocardial infarction (AMI). Circulating levels of miR-328 and miR-134 were detected by quantitative real-time PCR in plasma samples from 359 AMI patients and 30 healthy volunteers. Concentrations of high-sensitivity cardiac troponin T (hs-cTnT) were measured using electrochemiluminescence-based methods. MiRNAs were assessed for discrimination of a clinical diagnosis of AMI and for association with primary clinical endpoint defined as a composite of cardiogenic death and development of heart failure within 6 months after infarction. Results showed that levels of plasma miR-328 and miR-134 were significantly higher in AMI patients than in healthy controls. Receiver operating characteristic curve analyses showed significant diagnostic value of miR-328 and miR-134 for AMI. However, neither of them was superior to hs-cTnT for the diagnosis. Additionally, increased miRNA levels were strongly associated with increased risk of mortality or heart failure within 6 months for miR-328 (OR 7.35, 95 % confidence interval 1.07-17.83, P < 0.001) and miR-134 (OR 2.28, 95 % confidence interval 1.03-11.32 P < 0.001). In conclusion, circulating miR-328 and miR-134 could be potential indicators for AMI, and the miRNA levels are associated with increased risk of mortality or development of heart failure.

Left ventricular remodeling after acute myocardial infarction (AMI) is associated with adverse prognosis. It is becoming increasingly clear that circulating miRNAs could be promising biomarkers for various pathological processes in the heart, including myocardial infarction, myocardial remodeling and progression to heart failure. In the present study, a total of 359 consecutive patients were recruited. Plasma samples were collected on admission. Echocardiographic studies were performed during the admission and at six months follow-up after AMI. Remodeling was defined as an at least 10% increase from baseline in the left ventricular end-diastolic volume. Plasma miRNA levels were assessed for association with six months mortality or development of heart failure. Results showed that levels of plasma miR-208b and miR-34a were significantly higher in patients with remodeling than those without. Increased miRNA levels were strongly associated with increased risk of mortality or heart failure within six months for miR-208b (OR 17.91, 95% confidence interval = 2.07–98.81, p = 0.003), miR-34a (OR 4.18, 95% confidence interval = 1.36–12.83, p = 0.012) and combination of the two miRNAs (OR 18.73, 95% confidence interval = 1.96–101.23, p = 0.000). The two miRNA panels reclassified a significant proportion of patients with a net reclassification improvement of 11.7% (p = 0.025) and an integrated discrimination improvement of 7.7% (p = 0.002). These results demonstrated that circulating miR-208b and miR-34a could be useful biomarkers for predicting left ventricular remodeling after AMI, and the miRNA levels are associated with increased risk of mortality or heart failure.